Astellas Pharma Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALPMY research report →
Companywww.astellas.com
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant.
- CEO
- Naoki Okamura
- IPO
- 2009
- Employees
- 14,754
- HQ
- Tokyo, JP
Price Chart
Valuation
- Market Cap
- $26.05B
- P/E
- 14.27
- P/S
- 1.94
- P/B
- 2.27
- EV/EBITDA
- 7.16
- Div Yield
- 3.37%
Profitability
- Gross Margin
- 76.08%
- Op Margin
- 18.92%
- Net Margin
- 13.63%
- ROE
- 17.44%
- ROIC
- 12.08%
Growth & Income
- Revenue
- $2.27T · 18.61%
- Net Income
- $309.12B · 509.13%
- EPS
- $172.56 · 508.68%
- Op Income
- $445.01B
- FCF YoY
- 293.05%
Performance & Tape
- 52W High
- $17.35
- 52W Low
- $9.11
- 50D MA
- $15.36
- 200D MA
- $13.32
- Beta
- 0.08
- Avg Volume
- 174.31K
Get TickerSpark's AI analysis on ALPMY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ALPMY Coverage
We haven't published any research on ALPMY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ALPMY Report →